An IL-2 mutein engineered to promote expansion of regulatory T cells arrests ongoing autoimmunity in mice.
Ontology highlight
ABSTRACT: Interleukin-2 (IL-2) controls the homeostasis and function of regulatory T (Treg) cells, and defects in the IL-2 pathway contribute to multiple autoimmune diseases. Although recombinant IL-2 therapy has been efficacious in certain inflammatory conditions, the capacity for IL-2 to also activate inflammatory effector responses highlights the need for IL-2-based therapeutics with improved Treg cell specificity. From a panel of rationally designed murine IL-2 variants, we identified IL-2 muteins with reduced potency and enhanced Treg cell selectivity due to increased dependence on the IL-2 receptor component CD25. As an Fc-fused homodimer, the optimal Fc.IL-2 mutein induced selective Treg cell enrichment and reduced agonism of effector cells across a
SUBMITTER: Khoryati L
PROVIDER: S-EPMC7643170 | biostudies-literature | 2020 Aug
REPOSITORIES: biostudies-literature
ACCESS DATA